By Stephen Nakrosis
iRhythm Technologies said Wednesday it would collaborate with Alphabet Verily to improve screening, diagnosis and management of patients with atrial fibrillation.
About one-third of people with atrial fibrillation are unaware they have it, the companies said, and about 20% of those who experience stroke due to atrial fibrillation weren't diagnosed until they had a stroke.
"The iRhythm and Verily collaboration aims to address this significant, underserved population at risk for asymptomatic or silent AFib," the companies said.
Under the terms of the deal, iRhythm will make an upfront payment to Verily of $5 million and potential milestone payments of up to $12.75 million upon the achievement of various development and regulatory milestones.
--Write to Stephen Nakrosis at email@example.com